1-(2,5-difluorophenyl)-3-((1r,4r)-4-(4-(2-isopropoxyphenyl)piperazin-1-yl)cyclohexyl)urea | 919120-25-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(2,5-difluorophenyl)-3-((1r,4r)-4-(4-(2-isopropoxyphenyl)piperazin-1-yl)cyclohexyl)urea
• CAS: 919120-25-5
• 化学式: C₂₆H₃₄F₂N₄O₂
• 分子量: 472.578
• InChiKey: NXJNUASOAQRPKJ-MEMLXQNLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.01
• 重原子数：
  34.0
• 可旋转键数：
  6.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  56.84
• 氢给体数：
  2.0
• 氢受体数：
  4.0

反应信息

• 作为产物：
  描述：

  4-[4-(2-isopropoxy-phenyl)-piperazin-1-yl]-cyclohexylamine 、 异氰酸2,5-二氟苯酯 以 二氯甲烷 为溶剂， 生成 1-(2,5-difluorophenyl)-3-((1r,4r)-4-(4-(2-isopropoxyphenyl)piperazin-1-yl)cyclohexyl)urea 、 1-(2,5-difluorophenyl)-3-((1s,4s)-4-(4-(2-isopropoxyphenyl)piperazin-1-yl)cyclohexyl)urea
  参考文献：
  名称：

  (Phenylpiperazinyl)cyclohexylureas: Discovery of α1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS)

  摘要：

  Benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) can be effectively treated with alpha(1) adrenergic receptor antagonists. Unfortunately, currently marketed a, blockers produce CV-related side effects that are caused by the subtype non-selective nature of the drugs. To overcome this problem, it was postulated that an alpha(1a/1d) subtype-selective antagonist would bring more benefit for the treatment of BPH/LUTS. As a continuation of our effort to develop selective alpha(1a/1d) ligands, a series of (phenylpiperazinyl)cyclohexylureas was synthesized and evaluated for the ability to bind to three cloned human alpha(1)-adrenergic receptor subtypes. Several trans isomers were shown to have equal affinity for both ala, and alpha(1d) subtypes, with 14- to 47-fold selectivity versus the alpha(1b) subtype and > 15-fold selectivity versus dopamine D-2. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.11.068

文献信息

• Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds
  申请人：Chiu George

  公开号：US20070123542A1

  公开（公告）日：2007-05-31

  The present invention relates to substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds of Formula (I) and pharmaceutically acceptable forms thereof, as α 1a /α 1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.

  本发明涉及一种替代[4-(4-苯基哌嗪-1-基)-环己基]-脲化合物(I)及其药学上可接受的形式，作为α1a/α1d肾上腺素受体调节剂，用于治疗良性前列腺增生和下尿路症状。本发明还涉及包含所述新化合物的制药组合物、制备这些新化合物的新方法以及作为药物的新用途和治疗方法。
• US7517885B2
  申请人：——

  公开号：US7517885B2

  公开（公告）日：2009-04-14